01-30-04

Please type a plus sign (+) inside this box →

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

MANAGE	* /		Application Number	10/661,45	5
			Filing Date	Septemb	er 12, 2003
	TRANSMITTAL	-	First Named Inventor	NAKORN	, THANYAPHONG NA
	FORM		Group Art Unit		
	(to be used for all correspondence after ini	tial filing)	Examiner Name		
	Total Number of Pages in This Submissi	on 4 + REFS.	Attorney Docket Number	STAN-278	3
			ES (check all that apply		
	Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Documents	Cor and Coravir Coravi	ing-related Papers n to Convert to a ional Application of Attorney, Revocation se of Correspondence	1. 2. 3.	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): PTO/SB/08A Copies of cited references Postcard
	Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	umber of CD(s		
	SIGNA	TURE OF APPL	ICANT, ATTORNEY, O	K AGENT	
Reg. No		& FRANCIS LLP	<u>. </u>		
Signature	· James Sher	MIN			
Date	January 28, 2004				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL LABEL NO. EV333998106US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV333998106US

INFORMATION DISCLOSURE STATEMENT

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	STAN-278				
First Named Inventor	NAKORN, THANYAPHONG NA				
Application Number	10/661,455				
Confirmation No.					
Filing Date	September 12, 2003				
Group Art Unit					
Examiner Name					
Title: "MAMMALIAN MEGAKARYOCYTE PROGENITOR CELL"					

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-278 may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: _____January 28, 2004

Pamela J. Sherwood Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known		
					Application Number	10/661,455	
INFORMATION DISCLOSURE					Filing Date	September 12, 2003	
	STATEMENT BY APPLICANT				First Named Inventor	NAKORN, THANYAPHONG NA	
					Art Unit		
(use as many sheets as necessary)					Examiner Name		
Sheet	1	of	2	?	Attorney Docket Number	STAN-278	

			U.S. PATENT เ	OCUMENTS		
Examiner Initials'	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US- 6,465,247	Oct. 15, 2002	Weissman et al.		
		US-				

-		EODEIGI	N DATENT DOC	TIMENTS		
Examiner Initials'	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
		Country Code ³ –Number⁴–Kind Code ⁵ (if known)		Applicant of Cited Document		
		OTHER PRIOR ART—NO	ON PATENT LIT	ERATURE DOCUMENT	S	
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), The publisher city and/or country where published.					
	AKASHI et al., A CLONOGENIC COMMON MYELOID PROGENITOR THAT GIVES RISE TO ALL MYELOID LINEAGES, Nature, (2000), 404, 193-197-					
	BURSTEIN et al., CHARACTERISTICS OF MURINE MEGAKARYOCYTIC COLONIES IN VITRO, Blood, (1979), 54, 169-179 ~					
	ENVER et al., DO STEM CELLS PLAY DICE?, Blood, (1998), 92, 348-351 -					
GEORGOPOULOS et al., THE ROLE OF IKAROS GENE IN LYMPHOCYTE DEVELOPMENT AND HOMEOSTASIS, Annu. Rev. Immunol., (1997), 15:155-176 ~ LONG et al., IMMATURE MEGAKARYOCYTES IN THE MOUSE: IN VITRO RELATIONSHIP TO MEGAKARYOCYTE PROGENITOR CELLS AND MATURE MEGAKARYOCYTES, J. Cell. Physiol., (1982), 112, 339-344 ~						

Examiner	Date	
	Date	
Signature	Considered	
	00110100100	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449B/PTO			Complete if Known			
				Application Number	10/661,455		
	INFORMATION DISCL	-OSI	JRE	Filing Date	September 12, 2003		
STATEMENT BY APPLICANT				First Named Inventor	NAKORN, THANYAPHONG NA		
				Group Art Unit			
****	(use as many sheets as ned	<u>cessar</u>	ν)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	STAN-278		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
		LONG et al., ROLE OF PHORBOL DIESTERS IN IN VITRO MURINE MEGAKARYOCYTE COLONY FORMATION, J. Clin. Invest., (1984), 74, 1686-1692 →				
		MORRISON et al., THE AGING OF HEMATOPOIETIC STEM CELLS, Nat Med, (1996), 2, 1011-1016				
		MORRISON et al., THE LONG-TERM REPOPULATING SUBSET OF HEMATOPOIETIC STEM CELLS IS DETERMINISTIC AND ISOLATABLE BY PHENOTYPE, Immunity, (1994), 1, 661-673				
		NA NAKORN <i>et al.</i> , MYELOERYTHROID-RESTRICTED PROGENITORS ARE SUFFICIENT TO CONFER RADIOPROTECTION AND PROVIDE THE MAJORITY OF DAY 8 CFU-S, <i>J. Clin. Invest.</i> , (2002), 109, 1579-1585 -				
		ORKIN et al., DEVELOPMENT OF THE HEMATOPOIETIC SYSTEM, Curr. Opin. Genet. Dev (1996) 6:597-602 →				
		PAULUS et al., POLYPLOID MEGAKARYOCYTES DEVELOP RANDOMLY FROM A MULTICOMPARTMENTAL SYSTEM OF COMMITTED PROGENITORS, Proc. Natl. Acad. Sci. USA, (1982), 79, 4410-4414 -				
		SINGH et al., GENE TARGETING REVEALS A HIERARCHY OF TRANSCRIPTION FACTORS REGULATING SPECIFICATION OF LYMPHOID CELL FATES, Curr. Opin. Immunol., (1996), 8:160-165 ~				
		SPANGRUDE et al. PURIFICATION AND CHARACTERIZATION OF MOUSE HEMATOPOIETIC STEM CELLS, Science, (1988), 241, 58-62 —				
		UCHIDA <i>et al.</i> , RAPID AND SUSTAINED HEMATOPOIETIC RECOVERY IN LETHALLY IRRADIATED MICE TRANSPLANTED WITH PURIFIED THY-1.1 ¹⁰ LIN ⁻ SCA-1 ⁺ HEMATOPOIETIC STEM CELLS, <i>Blood,</i> (1994), 83, 3758-3779				

	.,	
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.